OCULAR THERAPEUTIX, INC

The company is an integrated biopharmaceutical company focused on retinal diseases. Its investigational product candidate, AXPAXLI (also known as OTX-TKI), is an axitinib intravitreal hydrogel based on its proprietary ELUTYX bioresorbable hydrogel-based formulation technology. AXPAXLI is in a Phase 3 registrational program for wet age-related macular degeneration (wet AMD), referred to as the SOL program, and another Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR), referred to as the HELIOS program. The company also uses its ELUTYX technology in its commercial product DEXTENZA, an FDA-approved corticosteroid. DEXTENZA treats ocular inflammation and pain after ophthalmic surgery in adults and pediatric patients, and ocular itching from allergic conjunctivitis in adults and pediatric patients aged two years or older. Additionally, the company has a product candidate, OTX-TIC, a travoprost intracameral hydrogel, which completed a Phase 2 clinical trial for open-angle glaucoma (OAG) or ocular hypertension (OHT). DEXTENZA and the company's clinical development candidates typically integrate previously FDA-approved therapeutic agents, such as small molecules, into ELUTYX to provide local programmed release in the eye. The ELUTYX hydrogel technology has been used in humans since 1992 and has been used in over five million patients across eight FDA-approved treatments, demonstrating its safety and effectiveness. DEXTENZA, the first and only FDA-approved drug-eluting intracanalicular insert, has been used in nearly 750,000 eyes since its launch, with reported adverse events in approximately 2 of every 10,000 patients.